| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6420d04b0d68f339771080e32bd0fbc9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96447 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate |
1993-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79d24af1ea4255188bb33cef985fe633
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e30a5393c1ecbe0273c7682f2ca9dd7 |
| publicationDate |
2008-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2134750-C |
| titleOfInvention |
Truncated tissue factor and fviia or fvii activator for blood coagulation |
| abstract |
It has been discovered that it is possible to administer truncated tissue factor, not having the transmembrane region, (tTF) in combination with factor VIIa (FVIIa) or an activator of endogenous factor VII to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. The tTF is administered to produce up to 10 pg tTF/ml of plasma. The FVIIa or FVII activator is administered to produce levels of between 40 ng VIIa/ml and 700 ng FVIIa/ml of plasma. The effective dosages of both tTF and VIIa/factor VII activator are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs. |
| priorityDate |
1992-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |